



Testing the effectiveness of domestic violence interventions: Why randomised controlled trials are necessary but not sufficient

Gene Feder

www.bristol.ac.uk/capc

@capcbristol


How do we know that domestic violence interventions do more good than harm?

- Ask the people
 The intervention?
 - Trainers
 - clergy/doc
- Ask the people receiving the perpetrators, other familiar
- Measure the decition of the incomplete the decition of the i


Primary Care

Jniversity of

Randomise!



IRIS trial





Open Access Research



Cost-effectiveness of Identification and **OPEN** Referral to Improve Safety (IRIS), a domestic violence training and support programme for primary care: a modelling study based on a randomised controlled trial

> Angela Devine, 1 Anne Spencer, 2 Sandra Eldridge, 1 Richard Norman, 3 Gene Feder⁴

To cite: Devine A, Spencer A, Eldridge S, et al. Cost-effectiveness of identification and referral to improve safety (IRIS), a domestic violence training and support programme for primary care: a modelling study based on a randomised controlled trial. BMJ Open

2012;2:e001008. doi:10. 1136/bmjopen-2012-001008 Prepublication history for this paper is available online. To view this file please visit the journal online (http://dx. doi.org/10.1136/

bmjopen-2012-001008). Received 10 February 2012 Accepted 14 May 2012

This final article is available for use under the terms of the Creative Commons Attribution Non-Commercial 2.0 Licence: see http://bmjopen.bmj.com

end of article.

Correspondence to

a.devine@qmul.ac.uk

ABSTRACT

Objective: The Identification and Referral to Improve Safety (IRIS) cluster randomised controlled trial tested the effectiveness of a training and support intervention to improve the response of primary care to women experiencing domestic violence (DV). The aim of this study is to estimate the cost-effectiveness of this

Design: Markov model-based cost-effectiveness

Setting: General practices in two urban areas in the

Participants: Simulated female individuals from the general UK population who were registered at general practices, aged 16 years and older.

Intervention: General practices received staff training, prompts to ask women about DV embedded in the electronic medical record, a care pathway including referral to a specialist DV agency and continuing contact from that agency. The trial compared the rate of referrals of women with specialist DV agencies from 24 general practices that received the IRIS programme with 24 general practices not receiving the programme. The trial did not measure outcomes for women beyond the intermediate outcome of referral to specialist agencies. The Markov model extrapolated the trial results to estimate the long-term healthcare and societal costs and benefits using data from other trials and epidemiological studies.

Results: The intervention would produce societal cost savings per woman registered in the general practice of UK£37 (95% CI £178 saved to a cost of £136) over 1 year. The incremental quality-adjusted life-year was estimated to be 0.0010 (95% CI -0.0157 to 0.0101) per woman. Probabilistic sensitivity analysis found 78% of model replications under a willingness to pay For numbered affiliations see threshold of £20 000 per quality-adjusted life-year. Conclusions: The IRIS programme is likely to be costeffective and possibly cost saving from a societal perspective. Better data on the trajectory of abuse and

ARTICLE SUMMARY

Article focus

. The aim of this study was to assess the costeffectiveness of the IRIS training and support intervention for primary care clinicians from the UK societal and NHS perspectives.

The intervention is likely to be cost saving from a societal perspective with a high likelihood of being under a £20 000 per quality-adjusted lifeyear willingness to pay threshold.

Strengths and limitations of this study

- · We have minimised bias in estimating the effect size of the IRIS programme by basing it on a randomised controlled trial.
- By using epidemiological and cost data external to the trial, we were able to extrapolate from directly measured trial outcomes (DV disclosure and referral rates) to quality of life, health and economic outcomes
- The uncertainty of the transition probabilities based on assumptions was addressed by probabilistic sensitivity analysis, contributing to the robustness of the model.
- Important limitations of that data are the paucity of longitudinal studies measuring the trajectory of abuse and uncertainty about the effect of DV advocacy for women not living in a refuge or

the effect of advocacy are needed for a more robust

Trial registration: Current Controlled Trials,

Devine A, Spencer A, Eldridge S, et al. BMJ Open 2012;2:e001008. doi:10.1136/bmjopen-2012-001008

UK domestic violence trials





Trials can be systematically reviewed and pooled







Some limitations of trials

- Randomisation may be problematic for folk delivering the intervention and/or participants
- Conservative estimate of effect
- Generalisability limited by specific context of the trial [and need for individual participant recruitment]
- [Measured outcomes may not be the ones that matter to participants]

Non-randomised bias- and confounding-reducing designs



Qualitative research is valuable in its own right and complementary to trials.



Trials in the global South



IMAGE
micro-finance
+
community
engagement
+
gender norm
change



Programmes involving boys and men in violence prevention





Intervention evidence trajectories

epidemiology

systematic reviews and meta-analyses

RCTs + nested qualitative studies & economic analyses

guidelines and policy